Professor Dyfrig Hughes
Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil
- Papur › Ymchwil › Heb ei adolygu gan gymheiriaid
- Cyhoeddwyd
Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?
Hughes, D. & Hughes, D. A., 1 Tach 2006.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Use of PK-PD modelling to predict the impact of non-compliance
Hughes, D. & Hughes, D. A., 1 Tach 2003.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?
Hughes, D., Hughes, D. A., LaFleur.*, [. V., Salas, M. & Shinogle, J., 1 Mai 2007.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Papur › Ymchwil › Adolygwyd gan gymheiriaid
- Cyhoeddwyd
A Systematic Review of Patient Preferences for Subcutaneous Medications
Ridyard, C., Dawoud, D. & Hughes, D., Tach 2013.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur › adolygiad gan gymheiriaid
- Cyhoeddwyd
Identification Of Items For A Standardised Resource-Use Measure: Review Of Current Instruments
Thorn, J. C., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S. & Hollingworth, W., Tach 2015.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur › adolygiad gan gymheiriaid
- Cyhoeddwyd
Review of the Use of Resource Use Instruments Based on Patient Recall in Relation to Other Methods of Cost Estimation
Ridyard, C. & Hughes, D., Tach 2013.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur › adolygiad gan gymheiriaid
- Cyhoeddwyd
Review of the use of resource use instruments based on patient recall in relation to other methods of resource use estimation
Ridyard, C. & Hughes, D., Tach 2013.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur › adolygiad gan gymheiriaid
- Cyhoeddwyd
Screening log data can be used to inform protocol modifications, increasing patient recrutiment to a challanging clinical trial
Blair, J., Awoyale, L., Thornborough, K., Peak, M., Didi, M., Bedson, E., Hughes, D., Ridyard, C., Tat, T. & Gregory, J., Tach 2013.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur › adolygiad gan gymheiriaid
- Murlen › Ymchwil › Adolygwyd gan gymheiriaid
- Cyhoeddwyd
Carer-administration of as-needed sub-cutaneous medication for breakthrough symptoms in homebased dying patients: a UK study (CARIAD)
Wilkinson, C., Poolman, M., Roberts, J., Wee, B., Hiscock, J., Hughes, D., Nelson, A., Perkins, P., Johnstone, R. P., Reymond, E., Foster, B., O'Connor, J., Jones, S., Hoare, Z., Roberts, R., Byrne, A., Healy, S. & Lewis, P., 1 Medi 2017.Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid
- Cyhoeddwyd
Comparison of regression methods for the cost effectiveness analysis of clinical trials with a small population size: the sycamore and folated trials
Culeddu, G., Hughes, D. & Welton, N., 10 Gorff 2017.Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid
- Cyhoeddwyd
Core items for a standardised resource-use measure (ISRUM):expert Delphi consensus survey
Thorn, J., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S., Thornton, G. & Hollingworth, W., 7 Mai 2017, t. P265. 1 t.Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid
- Cyhoeddwyd
Health Economics Analysis Plans: Where Are We Now?
Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 3 Tach 2016, t. A397. 1 t.Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid
- Cyhoeddwyd
Health economics analysis plans: the current state of play
Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 7 Mai 2017, t. P144. 1 t.Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid
- Cyhoeddwyd
Patient-level information and costing systems (PLICS) as a source of routinely collected cost data for trial-based economic evaluations
Ridyard, C. & Hughes, D., 7 Mai 2017, t. P141. 1 t.Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid
- Crynodeb › Ymchwil › Adolygwyd gan gymheiriaid
- Cyhoeddwyd
Continuous subcutaneous insulin infusion compated to multiple daily injection regimens in children and yung people at diagnosis of type 1 diabetes: A pragmatic randomised controlled trial and economic evaluation (scipi trial)
Blair, J., Mckay, A., Ridyard, C., Thornborough, K., Bedson, E., Peak, M., Didi, M., Annan, F., John, G., Hughes, D. & Gamble, C., Medi 2017, t. 22-23.Allbwn ymchwil: Cyfraniad at gynhadledd › Crynodeb › adolygiad gan gymheiriaid
- Arall › Ymchwil › Adolygwyd gan gymheiriaid
- Cyhoeddwyd
Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa
Culeddu, G., Brogan, P. A. & Hughes, D., 2021.Allbwn ymchwil: Cyfraniad at gynhadledd › Arall › adolygiad gan gymheiriaid
- Adroddiad Comisiwn › Ymchwil › Heb ei adolygu gan gymheiriaid
- Cyhoeddwyd
A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.
Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
AWMSG criteria for appraising new medicines.
Hughes, D. & Hughes, D. A., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2009, 2009 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2009, 2009 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn